Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1995 Oct;173(4):1042-8.
doi: 10.1016/0002-9378(95)91324-6.

Underlying disorders associated with severe early-onset preeclampsia

Affiliations

Underlying disorders associated with severe early-onset preeclampsia

G A Dekker et al. Am J Obstet Gynecol. 1995 Oct.

Abstract

Objective: Our purpose was to determine whether patients with severe early-onset preeclampsia have hemostatic or metabolic abnormalities that are associated with a tendency to vascular thrombosis.

Study design: A total of 101 patients with a history of severe early-onset preeclampsia were tested at least 10 weeks post partum for the presence of hyperhomocysteinemia (methionine loading test), protein C, protein S, and antithrombin III deficiency, activated protein C resistance, lupus anticoagulant, and immunoglobulin G and/or M anticardiolipin antibodies.

Results: Of the 101 patients, 39 (38.6%) had chronic hypertension. Of the 85 patients tested for coagulation disturbances, 21 (24.7%) had protein S deficiency. Of the 50 patients tested for activated protein C resistance, 8 (16.0%) were positive. Of the 79 patients tested for hyperhomocysteinemia, 14 (17.7%) had a positive methionine loading test. Finally, 95 patients were tested for anticardiolipin antibodies; 27 (29.4%) had detectable immunoglobulin G and/or M anticardiolipin antibodies.

Conclusion: Patients with a history of severe early-onset preeclampsia should be screened for protein S deficiency, activated protein C resistance, hyperhomocysteinemia, and anticardiolipin antibodies, since these results may have an impact on counseling for and pharmacologic management in future pregnancies.

PubMed Disclaimer

Comment in

  • Factor V Leiden mutation and preeclampsia.
    Rigó J Jr, Nagy B, Fintor L. Rigó J Jr, et al. Am J Obstet Gynecol. 2002 Apr;186(4):853; author reply 853-4. doi: 10.1067/mob.2002.122442. Am J Obstet Gynecol. 2002. PMID: 11967524 No abstract available.

LinkOut - more resources